Transmission and Selection of Macrolide Resistant Mycoplasma genitalium Infections Detected by Rapid High Resolution Melt Analysis
Open Access
- 20 April 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e35593
Abstract
Mycoplasma genitalium (MG) causes urethritis, cervicitis and pelvic inflammatory disease. The MG treatment failure rate using 1 g azithromycin at an Australian Sexual Health clinic in 2007–9 was 31% (95%CI 23–40%). We developed a rapid high resolution melt analysis (HRMA) assay targeting resistance mutations in the MG 23S rRNA gene, and validated it against DNA sequencing by examining pre- and post-treatment archived samples from MG-infected patients. Available MG-positive pre-treatment (n = 82) and post-treatment samples from individuals with clinical treatment failure (n = 20) were screened for 23S rRNA gene mutations. Sixteen (20%) pre-treatment samples possessed resistance mutations (A2058G, A2059G, A2059C), which were significantly more common in patients with symptomatic azithromycin-treatment failure (12/26; 44%) than in those clinically cured (4/56; 7%), p<0.001. All 20 patients experiencing azithromycin-failure had detectable mutations in their post-treatment samples. In 9 of these cases, the same mutational types were present in both pre- and post-treatment samples indicating transmitted resistance, whilst in 11 of these cases (55%), mutations were absent in pre-treatment samples indicating likely selection of resistant isolates have occurred. HRMA was able to detect all mutational changes determined in this study by DNA sequencing. An additional HRMA assay incorporating an unlabelled probe was also developed to detect type 4 single-nucleotide polymorphisms found in other populations, with a slightly lower sensitivity of 90%. Treatment failure is associated with the detection of macrolide resistance mutations, which appear to be almost equally due to selection of resistant isolates following exposure to 1 g azithromycin and pre-existing transmitted resistance. The application of a rapid molecular assay to detect resistance at the time of initial detection of infection allows clinicians to shorten the time to initiate effective second line treatment. This has the potential to reduce transmission of resistant strains and to avoid sequelae associated with persistent untreated infection.Keywords
This publication has 32 references indexed in Scilit:
- Induced Macrolide Resistance in Mycoplasma genitalium Isolates from Patients with Recurrent Nongonococcal UrethritisJournal of Clinical Microbiology, 2011
- Comparison of Two Mycoplasma genitalium Real-Time PCR Detection MethodologiesJournal of Clinical Microbiology, 2011
- High Prevalence of Macrolide Resistance inMycoplasma pneumoniaeIsolates from Adult and Adolescent Patients with Respiratory Tract Infection in ChinaClinical Infectious Diseases, 2010
- Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysisJournal of Antimicrobial Chemotherapy, 2009
- Persistence of Mycoplasma genitalium Following Azithromycin TherapyPLOS ONE, 2008
- Detection of Macrolide Resistance inMycoplasma pneumoniaeby Real-Time PCR and High-Resolution Melt AnalysisAntimicrobial Agents and Chemotherapy, 2008
- Short tandem repeat sequences in the Mycoplasma genitalium genome and their use in a multilocus genotyping systemBMC Microbiology, 2008
- Azithromycin Failure inMycoplasma genitaliumUrethritisEmerging Infectious Diseases, 2006
- Sequence-Based Typing of Mycoplasma genitalium Reveals Sexual TransmissionJournal of Clinical Microbiology, 2006
- Use of TaqMan 5′ Nuclease Real-Time PCR for Quantitative Detection of Mycoplasma genitalium DNA in Males with and without Urethritis Who Were Attendees at a Sexually Transmitted Disease ClinicJournal of Clinical Microbiology, 2004